MGMT and central nervous system cancer: First, some clinical molecular features, such as O6-methylguanine (O6-MeG)-DNA methyltransferase (MGMT) status, which has been regarded as a robust predictor of prognosis in patients with glioma (35–37), were not included in the current analysis.